Gene Therapy Zynteglo denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Required Prior Authorization for Zynteglo — and What to Do

Blue Cross Blue Shield requires prior authorization (PA) for Zynteglo (betibeglogene spartacus) because it is a high-cost, specialty gene therapy. A prior-auth-required denial typically means the therapy was administered or requested without a completed PA approval, or that a PA was submitted but denied because the clinical submission did not satisfy all of BCBS's coverage criteria. This is a process-based hurdle, not a judgment that the therapy is inappropriate — and it is fully navigable with the right documentation.

## Why This Denial Is Appealable

If PA was denied (rather than simply not yet requested), you have the same appeal rights as any adverse benefit determination: ACA §2719 and ERISA §503 guarantee internal and external review. A PA denial must be based on clinical criteria that are disclosed to you; if those criteria are met in the patient's chart and the documentation package is complete, appeal success rates are meaningful.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline on your denial letter (typically 30 days for pre-service denials). Submit a complete clinical package that directly maps to every criterion in BCBS's PA policy.
• External review: If the internal appeal is denied, request IRO review under ACA §2719. The window is typically 4 months from the final adverse benefit determination — verify the exact date on your notice.
• Expedited option: If delay would seriously jeopardize health, request expedited review with a 72-hour turnaround for both internal and external review.
• Concurrent PA resubmission: If the original PA was incomplete rather than denied on clinical grounds, consider resubmitting a corrected PA simultaneously while the appeal is pending.

## Documentation to Gather

1. Complete diagnosis record: Genetic confirmation of transfusion-dependent beta-thalassemia, including genotype and clinical history. 2. Transfusion dependency documentation: Comprehensive transfusion logs with dates, frequency, and volumes — demonstrating the patient meets the transfusion-dependent definition used in the FDA label and BCBS policy. 3. Prior treatment history: Records of all prior standard therapies with dates, durations, responses, and reasons for inadequacy or discontinuation. 4. Clinical severity and organ assessment: Chart notes documenting iron burden, organ function, and the clinical rationale for pursuing gene therapy. 5. Prescriber medical-necessity letter: A detailed letter from the treating hematologist referencing the FDA-approved prescribing label criteria and the applicable hematology guideline organization's recommendations.

## Criteria-Mapping Structure

Request BCBS's published PA criteria for Zynteglo or gene therapy in beta-thalassemia before filing. Map each criterion to specific chart evidence:

| PA Criterion | Chart Evidence | |---|---| | Confirmed diagnosis of TDT | [Genetic report date and type] | | Transfusion dependency as defined in FDA label | [Transfusion log — frequency and volume] | | Adequate trial of standard prior therapy | [Therapy history with dates and outcomes] | | Treating specialist attestation | [Hematologist PA letter referencing FDA label and guidelines] |

For the exact eligibility thresholds BCBS applies, consult the plan's published PA criteria directly. For the exact clinical thresholds in the FDA indication, consult the FDA-approved prescribing label. Your prescriber should confirm that every threshold is documented in the chart before submitting.